Targeting immune checkpoints in lymphoma

Current Opinion in Hematology

Volumn 22, Issue 4, 2015, Pages 337-342

  Ansell, Stephen M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Immune checkpoint inhibitors; Lymphoma; Programmed cell death 1; Tumor microenvironment

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; IPILIMUMAB; NIVOLUMAB; PALLADIUM; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

B CELL LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; HELPER CELL; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LYMPHOMA; LYMPHOMA CELL; MACROPHAGE; MONOCYTE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; RECURRENT DISEASE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RECURRENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84942740737     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000158     Document Type: Review

References (74)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
2. Yang ZZ, Ansell SM. The tumor microenvironment in follicular lymphoma. Clin Adv Hematol Oncol 2012; 10: 810-818.
3. de Jong D, Fest T. The microenvironment in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 135-146.
4. Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011; 58: 69-80.
5. de Jong D, Koster A, Hagenbeek A, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009; 94: 70-77.
6. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
7. + T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720-726.
8. + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 5052-5059.
9. Wahlin BE, Sundstrom C, Holte H, et al. T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res 2011; 17: 4136-4144.
10. + T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13 (2 Pt 1) : 388-397.
11. Laurent C, Muller S, Do C, et al. Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: A 3-D tissue-imaging study. Blood 2011; 118: 5371-5379.
12. Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumorinfiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009; 27: 1470-1476.
13. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
14. - T cells. J Immunol 2007; 178: 4051-4061.
15. + regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145-10152.
16. +CD25 T cells. Blood 2007; 110: 2537-2544.
17. + T cells to T-regulatory cells. Int J Cancer 2009; 124: 239-244.
18. Yang ZZ, Novak AJ, Ziesmer SC, et al. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2009; 69: 5522-5530.
19. + regulatory T-cell population by non-Hodgkin lymphoma. Blood 2008; 111: 5359-5370.
20. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphoma-Associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-2174.
21. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, et al. A high tumor-Associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007; 13: 5784-5789.
22. +HLADR ( low)/-monocytes in B-cell non-Hodgkin lymphoma. Blood 2011; 117: 872-881.
23. + T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res 2014; 20: 2862-2872.
24. Ame-Thomas P, Le Priol J, Yssel H, et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: Role in the survival of malignant B cells. Leukemia 2012; 26: 1053-1063.
25. Hilchey SP, Rosenberg AF, Hyrien O, et al. Follicular lymphoma tumorinfiltrating T-helper (T (H) ) cells have the same polyfunctional potential as normal nodal T (H) cells despite skewed differentiation. Blood 2011; 118: 3591-3602.
26. Pangault C, Ame-Thomas P, Ruminy P, et al. Follicular lymphoma cell niche: Identification of a preeminent IL-4-dependent T (FH) -B cell axis. Leukemia 2010; 24: 2080-2089.
27. Jones EA, Pringle JH, Angel CA, Rees RC. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma 2002; 43: 1313-1321.
28. Montes-Moreno S. Hodgkin's lymphomas: A tumor recognized by its microenvironment. Adv Hematol 2011; 2011: 142395.
29. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-1826.
30. Greaves P, Clear A, Owen A, et al. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. Blood 2013; 122: 2856-2863.
31. Steidl C, Lee T, Shah SP, et al. Tumor-Associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010; 362: 875-885.
32. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells: A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Patho 1999; 154: 1685-1691.
33. Marri PR, Hodge LS, Maurer MJ, et al. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res 2013; 19: 6812-6819.
34. Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol 2013; 23: 410-421.
35. Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-243.
36. Stevenson FK, Krysov S, Davies AJ, et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313-4320.
37. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029-1037.
38. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010; 463: 88-92.
39. Quinn ER, Chan CH, Hadlock KG, et al. The B-cell receptor of a hepatitis C virus (HCV) -Associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745-3749.
40. Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
41. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
42. Harsini S, Beigy M, Akhavan-Sabbagh M, Rezaei N. Toll-like receptors in lymphoid malignancies: Double-edged sword. Crit Rev Oncol Hematol 2014; 89: 262-283.
43. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012; 367: 826-833.
44. Fabre-Guillevin E, Tabrizi R, Coulon V, et al. Aggressive non-Hodgkin's lymphoma: Concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome. Leuk Lymphoma 2006; 47: 603-611.
45. Charbonneau B, Maurer MJ, Ansell SM, et al. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinicbased case-control study. Cytokine 2012; 60: 882-889.
46. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood 2004; 104: 2247-2253.
47. + regulatory T cells. Nat Immunol 2003; 4: 330-336.
48. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-1061.
49. Yang ZZ, Grote DM, Ziesmer SC, et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest 2012; 122: 1271-1282.
50. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A 2010; 107: 14733-14738.
51. + T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
52. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity. J Exp Med 2010; 207: 2187-2194.
53. Yang ZZ, Grote DM, Ziesmer SC, et al. Soluble and membrane-bound TGF-bmediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS One 2013; 8: E59456.
54. Yang ZZ, Grote DM, Xiu B, et al. TGF-b upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 2014; 28: 1872-1884.
55. Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: Implications for targeted therapy. Clin Cancer Res 2012; 18: 1611-1618.
56. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood 2009; 114: 2149-2158.
57. Steidl C, Shah SP, Woolcock BW, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377-381.
58. Wilcox RA, Wada DA, Ziesmer SC, et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009; 114: 2936-2944.
59. Wahlin BE, Aggarwal M, Montes-Moreno S, et al. A unifying microenvironment model in follicular lymphoma: Putcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res 2010; 16: 637-650.
60. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
61. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182: 459-465.
62. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220-228.
63. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
64. + T cell-And IL-2-dependent mechanism. Immunity 1999; 11: 483-493.
65. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
66. Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-439.
67. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by nonhodgkin lymphomas and inhibits the activity of tumorassociated T cells. Clin Cancer Res 2011; 17: 4232-4244.
68. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009; 15: 6446-6453.
69. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1581-1588.
70. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol 2013; 31: 4199-4206.
71. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol 2014; 15: 69-77.
72. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319.
73. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. ASH Annual Meeting 2014; Abstract 291.
74. Moskowitz CH, Ribrag V, Michot JM, et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Preliminary results from a phase 1b study (KEYNOTE-013). ASH Annual Meeting 2014; Abstract 290.